



# Mid-term outcomes of Y incision annular root enlargement compared to traditional root enlargement techniques

Fatima Qamar, MD, MPH; Sahar Samimi, MD; Marcel Gugala, BS; Muskan Khan, BS; Ahmed Ahmed, MD, MPH; Taha Hatab, MD; Rody Bou Chaaya, MD; Neal Kleiman, MD; Sachin Goel, MD; Syed Zaid, MD; Ross Reul, MD; Mahesh Ramchandani, MD; Michael Reardon, MD; Marvin Atkins, MD.

# Disclosures


- The authors have no relevant disclosures.

# Background

- **Patient Prosthetic mismatch (PPM)** is defined as “a smaller than expected effective orifice area (EOA) in relation to the patient's body surface area (BSA) resulting in higher transvalvular gradients”.<sup>1</sup>  
- Higher incidence of PPM in Surgical Aortic Valve Replacement (SAVR) compared to Transcatheter Aortic Valve Replacement (TAVR).<sup>2,3</sup>
- **PPM is associated with**
  - Significant reduction in cardiac index<sup>4</sup>
  - Increased risk of mortality and heart failure rehospitalization after SAVR<sup>5</sup>
  - 2.3x increase in risk of structural valve degradation<sup>6</sup>
- **Prevention of PPM**
  - Valve substitution (sutureless, stentless or supra-annular bioprosthesis etc.)
  - Aortic Root enlargement
  - TAVR

# Surgical Techniques for Aortic Root Enlargement

- Nicks <sup>7</sup>
- Manouguian <sup>7</sup>
- Yang Y-incision <sup>8</sup>



**Figure 1**

**A)** Showcases the posterior view of aortic root enlargement through two techniques: Nicks and Manouguian. **B)** Displays a novel aortic root enlargement technique: Y-incision.

# Objectives

- PPM remains a significant problem in SAVR
- The Y-incision root enlargement technique was proposed to enlarge the annulus by 3-4 valve sizes
- We compare our early results using Y- annuloplasty with traditional root enlargement (Nicks or Manouguian).

# Methods

- Building institutional database
- Clinical information extracted from chart reviews
- Parameters collected:
  - Surgery type
  - Demographic characteristics
  - Procedural characteristics
  - 30-day & one-year outcomes



# Results

## Demographics & comorbidities

	Total N=111	Traditional N=60	Yang N=51	p-value
<b>Age</b>	64.68 (11.82)	64.90 (9.71)	64.43 (14.00)	0.84
<b>Sex</b>				<b>0.005</b>
<b>Female</b>	76 (68.47%)	48 (80.00%)	28 (54.90%)	
<b>Male</b>	35 (31.53%)	12 (20.00%)	23 (45.10%)	
<b>Race</b>				0.85
<b>White</b>	93 (83.78%)	49 (81.67%)	44 (86.27%)	
<b>Black/African American</b>	11 (9.91%)	7 (11.67%)	4 (7.84%)	
<b>Asian</b>	4 (3.60%)	2 (3.33%)	2 (3.92%)	
<b>Other</b>	3 (2.70%)	2 (3.34%)	1 (1.96%)	
<b>BMI</b>	30.50 (7.50)	30.75 (8.62)	30.20 (5.98)	0.70
<b>Presence of diabetes</b>	47 (42.34%)	23 (38.33%)	24 (47.06%)	0.35
<b>Presence of prior MI</b>	11 (9.91%)	3 (5.00%)	8 (15.69%)	0.060
<b>Presence of renal failure</b>	4 (%)	2 (%)	2 (%)	0.87
<b>Presence of endocarditis</b>	10 (9.01%)	1 (1.67%)	9 (17.65%)	<b>0.003</b>
<b>Previous Cardiac Interventions</b>	41 (40.20%)	15 (28.30%)	26 (53.06%)	<b>0.011</b>
<b>Previous SAVR/TAVR</b>				0.55
<b>Aortic valve replacement; surgical</b>	29 (74.36%)	13 (76.47%)	16 (72.73%)	
<b>Aortic valve replacement; transcatheter</b>	6 (15.38%)	2 (11.76%)	4 (18.19%)	
<b>Redo Sternotomy</b>	30 (27.03%)	14 (23.33%)	17 (33.33%)	0.18
<b>Presence of Heart Failure</b>	50 (56.82%)	24 (52.17%)	26 (61.90%)	0.36
<b>NYHA</b>				0.49
<b>Class I</b>	18 (18.56%)	11 (20.75%)	7 (15.91%)	
<b>Class II</b>	34 (35.05%)	19 (35.85%)	15 (34.09%)	
<b>Class III</b>	40 (41.24%)	19 (35.85%)	21 (47.73%)	
<b>Presence of Cardiac Arrhythmia</b>	20 (22.99%)	7 (15.56%)	13 (30.95%)	0.088

# Results

## Operative characteristics

	Total N=111	Traditional N=60	Yang N=51	p-value
<b>Incidence of Surgery</b>				0.40
<b>First cardiovascular surgery</b>	77 (70.00%)	45 (75.00%)	32 (64.00%)	
<b>First re-op cardiovascular surgery</b>	26 (26.36%)	13 (21.67%)	16 (32.00%)	
<b>&gt; 1 re-op cardiovascular surgery</b>	4 (3.60%)	2 (3.33%)	2 (4.00%)	
<b>Status</b>				0.47
<b>Elective</b>	82 (73.87%)	46 (76.67%)	36 (70.59%)	
<b>Urgent</b>	29 (26.13%)	14 (23.33%)	15 (29.41%)	
<b>Procedure Category</b>				<b>0.028</b>
<b>AVR+CAB</b>	16 (15.53%)	9 (15.79%)	7 (15.22%)	
<b>AVR+MVR</b>	11 (10.68%)	1 (1.75%)	10 (21.74%)	
<b>Isolated AVR</b>	71 (68.93%)	43 (75.44%)	28 (60.87%)	
<b>Cardiopulmonary Bypass Time (min)</b>	153.51 (59.28)	129.51 (48.60)	182.41 (58.48)	<b>&lt;0.001</b>
<b>Aortic Cross Clamp Time (min)</b>	118.37 (45.79)	104.71 (40.88)	135.17 (46.32)	<b>&lt;0.001</b>
<b>SAVR device type</b>				1.00
<b>Bioprosthetic</b>	83 (77.57%)	45 (77.59%)	38 (77.55%)	
<b>Mechanical</b>	24 (22.43%)	13 (22.41%)	11 (22.45%)	
<b>Bioprosthetic Valve Type</b>				0.47
<b>Stented</b>	81 (96.43%)	44 (97.78%)	37 (94.87%)	
<b>Sutureless/rapid deployment</b>	3 (3.57%)	1 (2.22%)	2 (5.13%)	
<b>Intraoperative Blood Products- Total Units</b>	2.72 (2.88)	2.69 (3.11)	2.75 (2.70)	0.94


# Results

## Post-Operative Outcomes


	Total N=111	Traditional N=60	Yang N=51	p-value
<b>Implanted Aortic Valve Size</b>	22.63 (2.04)	21.52 (1.63)	23.94 (1.67)	<b>&lt;0.001</b>
<b>Aortic Gradient-Mean</b>	11.64 (5.68)	12.05 (5.18)	11.22 (6.19)	0.23
<b>Effective Orifice Area</b>	1.71 (0.45)	1.60 (0.40)	1.81 (0.49)	<b>0.05</b>
<b>Total Postoperative Ventilation Hours</b>	53.37 (172.27)	36.83 (121.30)	65.08 (201.39)	0.50
<b>30-day Readmission to ICU</b>	5 (5.75%)	3 (6.67%)	2 (4.76%)	0.70
<b>30-day In Hospital Post-Op Events</b>	61 (59.80%)	35 (61.40%)	26 (57.78%)	0.71
<b>30-day Post-Op Bleeding/Tamponade</b>	5 (8.33%)	2 (5.88%)	3 (11.54%)	0.43
<b>30-day Post-Op Prolonged Ventilation</b>	18 (29.51%)	8 (22.86%)	10 (38.46%)	0.19
<b>30-day Post-Op Pleural Effusion</b>	18 (29.51%)	9 (25.71%)	9 (34.62%)	0.45
<b>30-day Post-Op AKI/ Renal Failure</b>	12 (20.00%)	6 (17.65%)	6 (23.08%)	0.60
<b>Mortality at 30 days post-op</b>	4 (3.6%)	1 (1.7%)	3 (6.00%)	0.50
<b>Cardiac specific mortality at one-year post-op</b>	6 (5.4%)	2 (3.33%)	4 (7.8%)	0.09
<b>One-year cardiac readmission</b>	23 (22.55%)	11 (20.75%)	12 (24.49%)	0.65
<b>Total Procedure Time (Hours)</b>	5.94 (2.00)	5.39 (1.65)	6.33 (2.15)	0.051
<b>Surgery to Discharge LOS (Days)</b>	12.43 (9.64)	10.65 (7.27)	14.56 (11.59)	<b>0.033</b>
<b>Total ICU Hours</b>	150.84 (182.15)	127.26 (172.80)	175.54 (190.39)	0.22
<b>Major Morbidity or Mortality</b>	20 (22.99%)	10 (22.22%)	10 (23.81%)	0.86



# Results



Y-incision Root Enlargement




Nicks/Manouguian Root Enlargement

**Demonstration of increase in native aortic annulus diameter versus prosthesis size after Y-incision annular enlargement and Nicks/Manouguian procedures.**

# Results

- **Multivariable analysis**



Multivariable analysis, adjusting for age, gender, endocarditis, and prior MI, showed no significant difference in mortality hazards at 30 days (p:0.14) and one year (p:0.26) between the two procedures.

**Demonstration of forest plot for hazard ratios in the Cox model.**

# Conclusions

- Our experience with 51 patients undergoing Y root enlargement shows similar perioperative outcomes after adjusting for comorbidities compared to traditional root enlargement techniques.
- The Y enlargement cohort was associated with a longer operative time and a more significant increase in aortic valve size.
- Further investigations are warranted to validate these early results and assess long-term effects.
- Y-incision more frequently in endocarditis and required multi-valve operations.

# References

1. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. *Heart*. 2006 Aug;92(8):1022-9.
2. Ghanta RK, Kron IL. Patient-prosthesis mismatch: surgical aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients with aortic stenosis. *J Thorac Dis*. 2016 Oct;8(10):E1441-E1443.
3. Abbas AE et al. Impact of Flow on Prosthesis-Patient Mismatch Following Transcatheter and Surgical Aortic Valve Replacement. *Circ Cardiovasc Imaging*. 2021 Aug;14(8):e012364.
4. Pibarot P et al. Impact of prosthesis-patient mismatch on hemodynamic and symptomatic status, morbidity and mortality after aortic valve replacement with a bioprosthetic heart valve. *J Heart Valve Dis*. 1998 Mar;7(2):211-8.
5. Sá MPBO et al. mSurgical aortic valve replacement and patient-prosthesis mismatch: a meta-analysis of 108 182 patients. *Eur J Cardiothorac Surg*. 2019 Jul 1;56(1):44-54.
6. Flameng W et al. Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves. *J Thorac Cardiovasc Surg*. 2014 Apr;147(4):1219-24.
7. Grubb KJ. Aortic root enlargement during aortic valve replacement: Nicks and manouguian techniques. *Operative Techniques in Thoracic and Cardiovascular Surgery*. 2015;20(3):206-218.
8. Yang B, Ghita C, Palmer S. Y-incision aortic root enlargement with modified aortotomy upsizing the annulus by 5 valve sizes. *Ann Thorac Surg*. 2022;114(6):e479-e481